FDA delays decision on Lilly RA hopeful
Review extended by three months.
X
FDA delays decision on Lilly RA hopeful
https://pharmaphorum.com/news/fda-delays-decision-potential-lilly-ra-blockbuster/
Rheumatoid arthritis
Challenge to UK Humira patent begins
Samsung to take on patent thicket surrounding Humira.
AbbVie bullish on Humira and near-term pipeline
Sales of Humira could peak above $18 billion – CEO
Roche’s Mabthera faces cut-price competition in EU
Blockbuster likely to face cheap near-copy for first time.
EU regulators back Lilly’s blockbuster RA pill
Pill could generate $2 billion sales.
Ablynx in talks with partners for RA drug
Biotech suffered setback after AbbVie decided against partnership.
Sanofi/Regeneron RA drug rejected in US
FDA has concerns over Sanofi manufacturing plant.
J&J says ready to fend off Remicade competitor
Pfizer’s rival launch should be considered “at risk”, says J&J